Company intelligence / Profile preview

Accro Bioscience

Suzhou（苏州）, Jiangsu Province（江苏省）, 中国（China）accropeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Accro Bioscience has advanced multiple small molecule programs into clinical trials. AC-101 has completed Phase I with strong safety/PK data and is in Phase Ib for UC; AC-201 is in Phase II for psoriasis and NIU; AC-003 has completed Phase I with positive results and is in aGVHD trials. The company holds global rights to its assets with over 20 patents issued worldwide

Therapeutic areas: GastroenterologyOphthalmologyImmunologyDermatology
Modalities: Small molecules (notably selective kinase inhibitors such as RIPK2, TYK2/JAK1, and RIPK1 inhibitors)
Industry: Biotech

Drug pipeline

4 assets

AC-003

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Accro Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accro Bioscience.

Explore the full profile